PIRRIST: Patient and public involvement (PPI) to enhance recruitment and retention in surgical trials by Crocker, Joanna C et al.
RESEARCH Open Access
Patient and public involvement (PPI) in UK
surgical trials: a survey and focus groups
with stakeholders to identify practices,
views, and experiences
Joanna C. Crocker1,2,3* , Keira Pratt-Boyden4,5, Jenny Hislop1, Sian Rees6, Louise Locock7,5, Sophie Olszowski8,
Alan Chant9, Shaun Treweek7, Jonathan A. Cook10,3, Kerry Woolfall11,12, Nicola Farrar13,14, Jennifer Bostock15
and Richard Bulbulia16,17,18
Abstract
Background and aims: Historically, patient and public involvement (PPI) in the design and conduct of surgical
trials has been absent or minimal, but it is now routinely recommended and even required by some research
funders. We aimed to identify and describe current PPI practice in surgical trials in the United Kingdom, and to
explore the views and experiences of surgical trial staff and patient or public contributors in relation to these
practices. This was part of a larger study to inform development of a robust PPI intervention aimed at improving
recruitment and retention in surgical trials.
Methods: Our study had two stages: 1) an online survey to identify current PPI practice in active UK-led, adult
surgical trials; and 2) focus groups and interviews with key stakeholders (surgical trial investigators, administrators,
and patient or public contributors) to explore their views and experiences of PPI.
Results: Of 129 eligible surgical trial teams identified, 71 (55%) took part in the survey. In addition, 54 stakeholders
subsequently took part in focus groups or interviews. Sixty-five (92%) survey respondents reported some kind of
PPI, most commonly at the design and dissemination stages and in oversight or advisory roles. The single most
common PPI activity was developing participant information sheets (72%). Participants reported mixed practice and
views on a variety of issues including the involvement of patients versus lay members of the public, recruitment
methods, use of role descriptions and payment for the time of PPI contributors. They suggested some solutions,
including the use of written role descriptions and databases of potential PPI contributors to aid recruitment.
Conclusions: UK surgical trials involve patients and members of the public in a variety of different ways, most
commonly at the beginning and end of the trial lifecycle and in oversight or advisory roles. These are not without
challenges and there remain uncertainties about who best to involve, why, and how. Future research should aim to
address these issues.
Keywords: Patient and public involvement (PPI), Surgery, Survey, Focus group, Clinical trial
* Correspondence: joanna.crocker@phc.ox.ac.uk
1Health Experiences Research Group, Nuffield Department of Primary Care
Health Sciences, University of Oxford, Oxford, UK
2NIHR Oxford Biomedical Research Centre, Oxford, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Crocker et al. Trials          (2019) 20:119 
https://doi.org/10.1186/s13063-019-3183-0
Lay summary
Patient and public involvement (or ‘PPI’ for short)
means researchers working with patients and members
of the public in all or any parts of research. This could
include choosing the research topic, prioritising from a
list of research ideas, designing, planning and doing re-
search, and communicating the findings of research to
different groups of people. PPI is becoming increasingly
common in health research, including clinical trials,
which are a common way of testing new medicines and
other treatments.
This paper describes a survey we did to find out what
kind of PPI is happening in 71 surgical trials in the
United Kingdom. (By ‘surgical trials’ we mean clinical
trials which test a new type of surgery, or some other
treatment in patients who are having or have had sur-
gery.) We also talked to 54 people interested in surgical
trials, to find out what they think about PPI, and how it
could be improved.
Almost all the surgical trials in our survey (92%) were
doing some kind of PPI. This was most common at the
beginning of the trial (helping to design it) and at the
end of the trial (helping to communicate the findings to
different groups of people). It was more common for pa-
tients and members of the public to be involved as inde-
pendent advisers than as members of the trial team. The
most common thing they were asked to do was help de-
sign the patient information sheet. This is the informa-
tion given to patients when they are invited to take part
in a clinical trial.
The people we spoke to had experienced some chal-
lenges with PPI in surgical trials and had different opin-
ions about how PPI should be done. These included
whether to involve patients with the health condition be-
ing studied or lay members of the public, how to find
patients and members of the public to be involved, and
whether or not to pay them for their time. They also
suggested some ways PPI could be improved, such as
having written ‘job’ descriptions and building up a data-
base of people interested in being involved.
Some questions remain about who best to involve
and how, and we hope future research will be able to
answer these.
Background
Patient and public involvement (PPI) in research has
been defined as ‘research being carried out “with” or
“by” members of the public [including patients] rather
than “to”, “about” or “for” them’ [1]. This includes, for
example, working with research funders to prioritise re-
search, offering advice as members of a project steering
group, commenting on and developing research mate-
rials, and undertaking interviews with research partici-
pants [1]. Clinical trials in the UK have experienced a
recent surge in PPI activity, partly because the National
Institute for Health Research (NIHR) now expects active
PPI in the research it funds [2]. There is also a new re-
search agenda for PPI in clinical trials [3] and resources
to facilitate the planning, reporting, and evaluation of
PPI [4–6].
Despite an increasing focus on the importance of PPI
in trials, in a cohort investigation of NIHR- funded trials
conducted between 2006 and 2010 only 25% of surgical
intervention trials detailed PPI in the outline grant
application, compared with 75% of other clinical trials
(p = 0.01) [7]. Similarly, in a systematic review of PPI in
surgical trials in 2014, PPI was rarely reported in publi-
cations [8], although an absence of reporting does not
necessarily mean an absence of PPI. In this study, we
sought to: 1) identify and describe current PPI prac-
tice in surgical trials; and 2) explore the views and
experiences of surgical trial staff and PPI contributors
(involved patients and members of the public) in
relation to these practices, including their advantages
and disadvantages.
This study comprises the first and second stages of a
larger project funded by the MRC Network of Hubs for
Trials Methodology Research to develop a PPI interven-
tion aimed at enhancing recruitment and retention in
surgical trials (PIRRIST) [9]. In order to develop an ef-
fective intervention, we needed to first identify baseline
PPI activity among UK surgical trials.
Methods
Stage 1: survey
The primary objective of this survey was to ascertain
current PPI practice in UK surgical trials. We also ex-
plored respondents’ attitudes towards PPI.
Survey design
Informed by a framework developed by Oliver et al. [10]
and the findings of qualitative research led by a
co-author (LL) on the experiences of PPI contributors in
medical and health research [11–13], we agreed that the
following themes would be included in the survey:
 Rationale for including or not including PPI
 Role(s) of PPI contributors
 Number of PPI contributors involved
 Activities undertaken by PPI contributors
 Mode(s) of interaction between PPI contributors
and researchers
 PPI contributor characteristics (e.g. person with
condition under study, lay person, etc.)
 Methods used to recruit PPI contributors
 Presence or absence of written documentation
outlining PPI roles
 Support/guidance/resources used to inform PPI
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 Funding for PPI
 Respondent’s beliefs about PPI
 Lessons learned from respondents’ experiences
of PPI
Where possible, we used or adapted items from exist-
ing PPI questionnaires (from outside surgical research)
to formulate our initial survey questions [7, 14–19]. We
then piloted the survey iteratively with a convenience
sample of 13 trial staff, including nine trial managers
and four clinical investigators. Cognitive debriefing,
namely the ‘think aloud’ technique, was used with each
pilot participant (either face-to-face or by telephone) to
identify difficulties in interpreting or responding to
questions. Piloting continued until no further changes
were required. The final survey (Additional file 1) took
participants 10–15min to complete. It mainly consisted
of closed questions, with optional free-text comment
boxes on every page.
As a starting point, we used the definition of PPI pro-
vided by INVOLVE [1] (a national, government-funded
advisory group for PPI in health and social care re-
search) and added further clarification during piloting.
The final definition of PPI used in the survey is shown
in Table 1.
Identification of eligible trials
Trials eligible for the survey were active, UK-led trials of
surgical interventions or other interventions in adult
surgical patients. ‘Active’ meant that they were in set-up
(i.e. funded and pending regulatory approvals), open to
recruitment, or closed to recruitment and in follow-up.
Eligible trials were identified in three ways:
1. A search of the UK Clinical Research Network
(CRN) online database of portfolio studies [20]
listed under the ‘surgery’ specialty. The UK CRN
portfolio of studies consists of high-quality research
studies that are eligible for consideration for
support (in developing, setting up, and delivering
high-quality clinical research) from the NIHR-funded
Clinical Research Network in England. At the time of
this survey, the database was publicly available via the
UK CRN website.
2. The Royal College of Surgeons portfolio of surgical
trials in England.
3. Knowledge of eligible trials through personal
connections.
Survey delivery
We identified 129 eligible trials and sent a personal
email invitation to the primary contact listed for each
eligible trial. In the invitation, potential participants were
offered a £10 high street shopping voucher or academic
book voucher as a ‘thank you’ for their time; this was
sent by post on completion of the survey. Personal email
reminders were sent to non-responders at 2 and 4 weeks
after the initial invitation. The survey was open for a
total of 12 weeks between September and November
2015. Our participant information sheet was based on a
user-tested template developed by Knapp et al. [21], and
we used the Bristol Online Surveys tool [22] to deliver
the survey. The identity and contact information of re-
spondents were requested at the end of the survey to
enable us to keep in touch with respondents and deliver
thank-you vouchers, but this was optional and respon-
dents could complete the survey anonymously if pre-
ferred. However, we did ask for the trial name or
acronym at the beginning of the survey to check
eligibility and carry out a response bias analysis. Respon-
dents did not have to complete the survey in one sitting
(there was a ‘finish later’ option), but their responses were
not submitted until completion of the whole survey.
In the hope of increasing the response rate to personal
invitations, prior to and during the survey period we
carried out several awareness-raising activities among sur-
gical research staff: 1) seminars to staff audiences at six
academic surgical research centres in the UK (Oxford,
Aberdeen, Bristol, Birmingham, London, Leicester); 2) an
online blog published on the NIHR Oxford Biomedical
Research Centre website; 3) promotional flyers distributed
to delegates at the UK Trial Managers Network annual
meeting; 4) a national webinar hosted by the MRC
Network of Hubs for Trials Methodology Research—Trial
Conduct Working Group; 5) promoting the study via
Twitter; and 6) informing personal contacts.
Survey analysis
We exported the survey data into IBM SPSS Statistics
22 and generated simple statistical summaries of the
closed form responses to each survey item. Free-text
qualitative data were grouped thematically and used to
aid interpretation of the quantitative data where
relevant. Data were checked for inconsistencies and re-
spondents contacted for clarification where necessary
Table 1 Definition of patient and public involvement (PPI) used
in this survey
By ‘PPI’ we mean researchers consulting with or working alongside
members of the public, patients, service users, and/or carers in all or any
part(s) of the research process, including the choice of research topic,
design, planning, conduct, and/or dissemination of research. In this
survey we refer to these people as ‘PPI contributors’.
PPI contributors may be, for example, grant co-applicants, members of
the Trial Steering Committee or Trial Management Group, members of a
patient or lay advisory panel, or participants in a trial-specific consultation
exercise such as a focus group, survey, or interviews. Consultation exercises
may or may not use formal research methods.
By ‘PPI’, we do not mean researchers recruiting people to be
participants in the trial, or researchers disseminating information about
the trial to patients or the public.
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and if they had given their permission to be re-contacted
for this purpose. We explored whether trials funded by
the NIHR (fully or partially) and with later recruitment
start dates would be more likely to have PPI in the fund-
ing application. For both factors, a difference in the per-
centage of trials with PPI in the funding application was
calculated with the 95% confidence interval (CI) using
Newcombe’s model 10 using the rdci command in Stata
version 15.
Assessment of response bias
We hypothesised that our sample of respondents would
be biased towards those with experience of PPI in surgi-
cal trials (since the topic would be of greater interest to
people already doing PPI). In order to test this hypoth-
esis and estimate the degree of response bias, we ob-
tained relevant data from the National Research Ethics
Service (NRES) through a Freedom of Information
request for each trial invited to take part in the survey.
These data consisted of the responses (including
free-text comments) to question A14–1 of the NRES ap-
plication form: “In which aspects of the research process
have you actively involved, or will you involve, patients,
service users, and/or their carers, or members of the
public?” A researcher (JCC) used this information to
code each trial as ‘PPI’ or ‘No PPI’. A difference in the
percentage of trials with PPI between responders and
non-responders was calculated using the same method
as noted above.
Stage 2: focus groups
In the context of the wider PIRRIST project, the primary
objectives of this applied qualitative research were to
explore: 1) views and experiences (especially challenges)
of recruitment, retention, and PPI in surgical trials;
2) views about the impact of PPI on recruitment and re-
tention of surgical trial participants; and 3) possible ideas
for the PIRRIST intervention. This paper focuses on the
first of these objectives in relation to PPI.
Eligible participants were UK-based current surgical
trial staff (any role, including PPI coordinator) and PPI
contributors with combined experience of PPI, clinical
trials (any intervention) and surgery or surgical research.
Eligible trial staff were identified from stage 1 survey re-
spondents, open adverts (via email and Twitter) distrib-
uted to and cascaded by regional and national PPI and
surgical networks/groups, and our own professional con-
tacts. Prior to conducting the focus groups, we also pub-
lished a promotional article in the Bulletin of the Royal
College of Surgeons of England [23].
Interested potential participants were asked to indicate
which of four sites (Oxford, Aberdeen, Birmingham, or
Bristol) they would prefer to attend. Potential participants
at each site were then asked to complete a Doodle poll
showing their availability. Travel bookings and overnight
accommodation were offered to ensure that geography
was not a barrier. We aimed to recruit eight participants
per focus group with a diverse range of roles and experi-
ences; staff focus groups had to include at least one trial
manager, principal investigator, and research nurse. Dates
which best fulfilled these criteria were chosen. Potential
participants who were unable to join a focus group, as well
as the focus group participants themselves, were invited to
submit (additional) comments in writing if they wished.
To maximise participation by PPI contributors, those un-
able to attend a focus group were offered an alternative
one-to-one interview in person or by telephone. Focus
group and interview participants were offered a £20 high
street shopping voucher or book voucher as a ‘thank you’
for taking part.
Focus groups were facilitated by a non-clinical member
of the research team (JCC), who used a semi-structured
topic guide covering the following: experiences of PPI;
experiences of participant recruitment and retention;
participants’ views of the impact of PPI on participant re-
cruitment and retention (including how this happens);
and ideas for the PIRRIST intervention. The focus groups
were audio-recorded, and an observer (KPB) took notes to
aid transcription. The audio-recordings were transcribed
verbatim, checked, and anonymised before undergoing
thematic analysis [24]. The first full transcript was coded
deductively by three researchers independently (JCC,
KPB, JH) against the pre-specific topics of interest: views
and experiences of PPI; suggestions for improving PPI;
participant recruitment; participant retention; impact of
PPI on recruitment; impact of PPI on retention; other im-
pacts of PPI; ideas for PPI intervention. The coding was
discussed, agreed, and transferred to NVivo. The coding
reports (coded text within each of the pre-specified topics)
were then coded inductively by the same three re-
searchers, and a preliminary thematic framework was
agreed. This framework was then applied to subsequent
transcripts independently by two researchers (JCC and
KPB), who regularly discussed, agreed, and refined the
framework.
Combining stage 1 and stage 2 findings
Themes which emerged from analysis of the focus
groups were mapped against the themes covered in the
survey to identify areas of overlap. In this paper, we
present the findings under cross-cutting themes (i.e.
those for which we have information regarding both the
frequency of practice and people’s views and experiences
of the practice). Participant ID numbers are provided
where direct quotations are used, with ‘SR’ indicating a
stage 1 survey respondent, ‘PS’ indicating a stage 2 staff
participant, and ‘PP’ a stage 2 patient or lay participant.
The notation ‘[…]’ is used to indicate where verbatim
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text has been excluded from the quotation. In some
cases, details have been removed and replaced with
broad descriptors (e.g. ‘[medical condition]’) to ensure
anonymity.
PPI in this study
The idea for the PIRRIST study emerged from meetings
with an advisory panel for JCC’s research fellowship,
which was funded by the NIHR Oxford Biomedical
Research Centre to research PPI impact assessment. The
advisory panel included two patient advisers (including
author AC), who were involved in the group to ensure
that the research was relevant to, and informed by the
perspectives of, patients and members of the public.
They were chosen because of their long-term experience
of PPI and interest in assessing its impact. The decision
to undertake the PIRRIST study (and an accompanying
systematic review [25]) was in part due to our patient
advisers’ desire to measure the impact of PPI, particu-
larly on patient recruitment to clinical trials. Whilst the
study was underway, one patient adviser (MO) retired
and a third (RH) joined the group. These patient part-
ners provided input at six advisory group meetings and
email correspondence between meetings, and one (AC)
was co-applicant on the project grant and continued to
be a member of the study team throughout. A second
lay partner (JB) joined the study team once funding had
been secured. As well as helping to conceive of the
PIRRIST study, the patient partners and advisers helped
to design the overall study and its patient-facing mate-
rials (online survey, focus group topic guide, informa-
tion sheets, invitations, and adverts), promote the study
to wider patient/PPI groups, and interpret the findings.
As a team, we believe that PPI is worth doing but that
it should be evaluated to improve practice and maxi-
mise value.
Results
Stage 1 survey respondents
Of 129 eligible trials that were identified, and the pri-
mary contacts invited to take part, 71 (55.0%) partici-
pated in the survey. We were unable to source NRES
PPI data for 29 (22.5%) of the invited trials because the
question about PPI had not been implemented at that
time or NRES was unable to retrieve the data. For the
99 trials with NRES PPI data available, 49/56 (87.5%) survey
responders reported PPI or plans for PPI in the NRES
application form, compared with 33/43 (76.7%)
non-responders, with a difference in percentage of trials
with PPI input of 11% (95% CI −4 to 26%).
At the time of survey completion, 7 (9.9%) participat-
ing trials were in setup, 46 (64.8%) were open to recruit-
ment, and 18 (25.4%) were closed to recruitment and in
follow-up. Recruitment start dates ranged from July
2004 to June 2017 (median July 2013). Of these trials, 54
(76.1%) were funded by the National Institute for Health
Research, 6 (8.5%) by another public funder, 16 (22.5%)
by a charity, and 3 (4.2%) by industry. (These categories
are not mutually exclusive; 8 trials (11.1%) had multiple
funder types.) Cancer, cardiovascular disease, and mus-
culoskeletal conditions were the most common clinical
specialties (16 trials; 22.5% each).
The survey respondents included 40 (56.3%) trial
managers, 17 (23.9%) chief investigators, 6 (8.5%)
co-investigators, 6 (8.5%) other trial staff, and 2 (2.8%)
PPI coordinators. They represented a wide range of
views on PPI (Table 2), although the vast majority of re-
spondents agreed or strongly agreed that PPI is morally/
ethically the right thing to do (91.5%) and that PPI can
make a positive difference to surgical trials (87.3%).
Stage 2 focus group and interview participants
A total of 54 people (including 31 surgical trial staff, 21
PPI contributors, and 2 PPI coordinators) took part in
stage 2 between January and June 2016. We conducted
six focus groups: four with surgical trial staff (at the
Table 2 Survey respondent beliefs about patient and public
involvement (PPI) (n = 71)
Number of trials (%)
PPI is morally/ethically the right thing to do
• Strongly agree 29 (40.8%)
• Agree 36 (50.7%)
• Undecided 2 (2.8%)
• Disagree 2 (2.8%)
• Strongly disagree 2 (2.8%)
PPI can make a positive difference to surgical trials
• Strongly agree 24 (33.8%)
• Agree 38 (53.5%)
• Undecided 6 (8.5%)
• Disagree 1 (1.4%)
• Strongly disagree 2 (2.8%)
PPI can improve the recruitment of participants to surgical trials
• Strongly agree 19 (26.8%)
• Agree 37 (52.1%)
• Undecided 13 (18.3%)
• Disagree 1 (1.4%)
• Strongly disagree 2 (2.8%)
PPI can improve the retention of participants in surgical trials
• Strongly agree 16 (22.5%)
• Agree 32 (45.1%)
• Undecided 21 (29.6%)
• Disagree 1 (1.4%)
• Strongly disagree 1 (1.4%)
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universities of Oxford, Aberdeen, Birmingham, and Bris-
tol) and two with PPI contributors (both at the public li-
brary of Birmingham). In addition to the focus groups,
we carried out seven one-to-one interviews with PPI
contributors (two face-to-face and five by telephone)
and received 11 written contributions.
Frequency of PPI in UK surgical trials
Sixty-five (91.5%) surveyed trials reported that there
was, or had been, PPI in the trial according to our defin-
ition. The most commonly cited reasons for including
PPI in the trial were that it was considered morally/
ethically the right thing to do, that it was believed to
result in better research, and that it was required by the
funder(s) (Table 3). Five of the six trials which did not
have any PPI gave at least one reason: PPI was not a re-
quirement when the trial was set up (n = 4); PPI was un-
likely to improve the trial (n = 3); and the trial team had
tried but failed to identify PPI contributors (n = 1).
Who were the PPI contributors?
Of the 71 surveyed trials, three-quarters had PPI con-
tributors with personal experience of the condition
under study but who did not fulfil the eligibility criteria
for that trial, while a minority of trials had other pa-
tient(s), carer(s) or service user(s), lay members of the
public, or patients who fulfilled the eligibility criteria for
the trial (Fig. 1).
Stage 2 participants discussed the merits of having PPI
contributors with experience of the medical condition
under study versus lay members of the public with no
such experience. In focus group 4 (trial staff ), lay
members of the public were described positively as
‘reminding the professionals about the patient’ (PS25),
‘almost like a mediator’ between researchers and patients
(PS24), and ‘a neutral kind of person’ (PS24). It was sug-
gested that a lay person might feel more able to chal-
lenge the research team than a patient:
‘I wonder if a lay person as well, wouldn’t have that…
maybe that sort of feeling of power imbalance as
much as a patient would, with the other—the
academics and the professionals—they might just be,
‘Well, I have no sort of experience of this and I have
no reason to not say anything to upset this person
because I'm never going to be seen by them, or I'm
never going be in that sort of community,’ so maybe
they would feel more able to speak up in some ways.’
(PS24, PPI coordinator, focus group 4)
Lay people were also seen as more able to commit to
long-term trials than patients with serious conditions:
‘…if you’ve got palliative patients they can’t sort of sit on
steering group and the trials that go on for years.’ (PS25,
PPI coordinator, focus group 4).
However, lay people were sometimes perceived to have
an alternative agenda that could steer the focus away from
patients. One surgical investigator (PS28) gave an example
of PPI in setting a research agenda for a life-threatening
condition. Most contributors present at the meeting were
members of the public and were interested in a related,
more common condition which ‘doesn’t kill you’. This dis-
tortion ‘defined the whole day for us’ and the smaller
group of patients present at the meeting felt frustrated
that their life-threatening condition was not prioritised
more in discussions. The investigator concluded that ‘if
you’re dealing with lay people you have to understand
their agenda—why are they there?’
Some participants felt PPI contributors should have
experience of the condition under study, or even be typ-
ical of the target population:
‘I can talk about what has happened to me [but] if
you suddenly said, right, will you go on a trial for
somebody who’s got earache or asthma, I wouldn’t
know, have a clue.’ (PP56, PPI contributor, interview)
‘I think it’s very important to recruit [PPI contributors]
who have experience of what the programme is about.
[…] There’s no, no point in asking a nurse what the
exhaust content of an internal combustion engine…’
(PP53, PPI contributor, interview)
‘We've got two patients who sit on our trial steering
committee, but they are professional patients—so
one's an ex-GP and one's an ex-university dean. […]
But I am very conscious that perhaps in some sense,
although they are real patients, they’ve both actually,
you know, had their surgical procedure that we're
doing the trial to look at, which is invaluable, but
they're not exactly, you know Joe Bloggs off the
street you know, they are professionals.’ (PS23, trial
manager, focus group 4)
Table 3 Reasons for including patient and public involvement
(PPI) in the trial (n = 65)
Number of trials (%)
Considered morally or ethically the right thing
to do
47 (66.2%)
Believed to result in better research 46 (64.8%)
Required by funder(s) 44 (62.0%)
To improve recruitment of participants to this trial 40 (56.3%)
To improve retention of participants in this trial 28 (39.4%)
Institutional policy 19 (26.8%)
PPI contributor(s) offered their services 2 (2.8%)
Do not know 1 (1.4%)
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However, patients or carers were sometimes felt to
have vested interests which could be problematic for the
trial team, especially if their role was unclear:
‘He [involved carer] wasn’t very clear about what his
role was I don’t think, and he kind of turned… he gave
the impression that he'd like to turn our trial—all our
trials, or all trials even—into trials into a particular sub-
section of the disease that his daughter had, and ended
up doing all sorts of research on his own, sending
emails to the chief investigator at all sorts of times.
"Ooh have you seen this, have you read this?" and so
on. And yeah, he could have been either better selected
or better informed.’ (PS13, trial manager, focus group 2)
‘I think you can sometimes get the people that attend
who've got a slightly alternative agenda and definitely
hope that it will give them better healthcare or give
them access and I think it's very hard to sort of keep
it… keep them back a little bit and not let them
completely take over the group…’ (PS06, research
nurse, focus group 1)
One patient on a trial management team spoke of the
need to involve the trial participants themselves, and the
difficulty of doing this:
‘I think that for people like myself actually working on
behalf of the patients in a trial management team for
instance, then we need access to the patients
somehow. In a way you feel a little bit distanced. […] I
have my own personal journey but I can't use that
particularly in the trial management teams that I'm
associated with. So, I like to think I can get a hold of
patients who are currently involved and actually are in
the actual trial participating, and that’s something
that’s a bit frustrating that we can't…it's not easy to
do that.’ (PP11, PPI contributor, focus group 6)
How were the PPI contributors recruited?
The most common way in which PPI contributors were
recruited was through asking people the trial team
already knew, particularly patients or former patients of
a clinician on the team (Table 4). Nearly half of the trials
approached an established group, service, or organisa-
tion, while very few used open adverts. In only two cases
did PPI contributors approach the trial team.
Fig. 1 PPI contributors (n = 71 trials)
Table 4 How was/were the patient and public involvement
(PPI) contributor(s) recruited? (n = 65 trials with some kind
of PPI)
Number of trials (%)
Asked person/people already known to
member(s) of the trial team
40 (61.5)
• Patient(s) or former patient(s) of a clinician
on the team
32 (49.2)
• PPI contributor(s) from a previous study 12 (18.5)
• Participant(s) from a previous study 4 (6.2)
• Acquaintance(s), friend(s) or relative(s) 4 (6.2)
• Participant(s) from this trial 2 (3.1)
• Other 2 (3.1)
• Do not know 1 (1.5)
Approached an established group, service,
or organisation
33 (50.8)
• A patient group or voluntary organisation 19 (29.2)
• An established PPI group in my research
centre/institution
9 (13.8)
• Research Design Service (RDS) 2 (3.1)
• Clinical Research Network (CRN) 2 (3.1)
• Other 4 (6.2)
Open invitation/advert (e.g. newspaper,
website, poster)
5 (7.7)
PPI contributor(s) approached the trial team 2 (3.1)
Other 1 (1.5)
Do not know 4 (6.2)
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Inviting patients already linked to a clinician on the
team was considered by stage 2 participants to be an ef-
fective way to recruit PPI contributors, but potentially
limiting the impact PPI could have, because it could re-
sult in ‘yes men’:
‘I advised the consultant to put—the PI [Principal
Investigator]—to put, you know, “consultant” on an
individual letter to patients from the database and I
am convinced that that did the trick. That people
had had that personal invitation to a lunch and a
mini-seminar really.’ (PP50, PPI contributor,
interview)
‘I think from my perspective, in my trial, the PPI
was identified by the CI [Chief Investigator], both
of them, because I've got two—one's a PMG
[Project Management Group] member and the
other one's a TSC [Trial Steering Committee]
member—and I would say that cronyism is
potentially a downside to that, because it's obvious
that the CI talks to them, out-with those meetings,
and they just agree with everything that happens in
the meeting, and with the [funder], are specifically
asked for their involvement in the reports and they
just say they're very happy with how everybody…
everybody's working really well, and that’s all they
say. […] So, I'm not sure that they're necessarily
the best people for my trial because they're yes
men and they aren’t necessarily providing bad news
for the team to consider.’ (PS20, trial manager,
focus group 3)
The recruitment of PPI contributors via established
patient or public groups, services, or organisations was
seen as providing several benefits including patients mo-
tivated to contribute, and access to a wider group of pa-
tients and communication platforms:
‘So, I would cling to that resource [patient support
groups], cos I think with all this because I think that if
they're motivated enough to go along to one of those
groups, they’ll be motivated enough probably to help
the PPI...’ (PS04, trial manager, focus group 1)
‘…we've used a patient charity that we have
connections with to raise awareness of the trial,
and it's quite a rare disease with not many people
who suffer from it, so that’s been quite useful. […]
We've had sort of consultation with groups of
patients that we've reached through the charity
that we probably wouldn’t have had if we hadn’t
been advertising them.’ (PS13, trial manager, focus
group 2)
However, some participants feared that PPI contribu-
tors from patient organisations might be too ‘professio-
nalised’ for the role:
‘We've had a variety of PPI people work on the trials,
and we've had one who was very involved with a
patient charity, and at times it feels like we're dealing
with a sort of professional PPI person rather than
somebody who is actually still a patient.’ (PS13, trial
manager, focus group 2)
‘Well I was just wondering what the group thought
about patient groups and representatives of patient
groups, because you can speak to, say, the head of a
patient group, who in theory speaks for their…you
know their entire community, and that person might
be a professional patient and might be, you know very
well educated and have gone back to represent the
views of people, you know all sorts of people. Do you
guys feel it's reasonable to talk to the head of that
patient group on the assumption that they do
represent their members, or is that not an appropriate
person to recruit?’ (PS28, investigator, focus group 4)
Paradoxically, professional skills and an ability to think
beyond their own patient experience were considered
useful or even necessary:
‘If your background is in management, if your
background is in academia or whatever, those skills
can be transferred to a multi-disciplinary panel where
you are on a same wavelength as academics or what-
ever. So, the skills come from not only your patient
experience which is experience engagement, but in-
volvement goes a bit deeper.’ (PP04, PPI contributor,
focus group 5)
‘We did some focus groups, well, it was a study
actually, at [hospital name], of what patients thought
of the [medical specialty] questionnaires and a lot of
them couldn’t get what we were saying: Is this
question sensible? Does it relate to your life? And they
just answered the question and they couldn’t reflect
on whether it was a sensible question or not.’ (PP50,
PPI contributor, interview)
Open advertisements were seen as good practice and
more inclusive, but could be challenging due to the add-
itional time required:
Female participant (unidentified): ‘I think a lot of the
time you’ve got to identify your PPI people before
you’ve even got the funding up and running do you
think?’
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Female participant (unidentified): ‘Yeah it's a very,
very early stage in that I don’t really know if you’ve
got time to advertise fully…’ (Focus group 3)
However, open advertisements could still feel frustrat-
ingly exclusive, as voiced by one patient participant who
applied for a PPI opportunity advertised as ‘first come,
first served’:
‘…on first come, first served, it’s quite—the difficulties
of that is, one, you have to be on email, two, you have
to look at your email at the right time and they did
say they expected it to be well over-subscribed before
the final deadline…’ (PP56, PPI contributor, interview)
Several participants mentioned that a database or
‘pool’ of interested people would be a useful recruitment
resource:
‘Having a database of patients who are willing to be
involved in the PPI process and the specialities in
which they have user experience would be a really
useful tool to have in each research department.’
(PS50, research nurse, email contribution)
‘The only way to do that is for each [university]
department to have their standing PPI group. Of
patients, as recent as possible.’ (PP50, PPI contributor,
interview)
Where did PPI feature in the research process?
Of the 71 surveyed trials, most had PPI in research
design (82%) and the dissemination of findings (59%),
while a minority of trials had PPI in undertaking the
research (24%) and in the analysis and/or interpret-
ation of results (31%). By far the most common PPI
activity was developing participant information mate-
rials such as information sheets and consent forms
(72% of trials). However, PPI limited to developing
patient information sheets was generally regarded as
tokenistic:
‘It’s very easy for it [PPI] to be tokenistic, and I think
if you’ve just got like one individual who occasionally
comes along to a trial team and is just shown an
information leaflet and stuff, and things like that, then
you don’t properly engage them there...’ (PS12, trial
manager, focus group 2)
‘I've definitely seen a shift in the level of involvement
of PPI. It has really, really changed. At the start it did
almost feel like it was…I probably shouldn’t say this,
but it did almost feel like it was a tick box exercise, it
was something that the funders asked for, so you had
to have a patient representative on your TMG [Trial
Management Group], possibly on your TSC [Trial
Steering Committee], and have them feed into your
PIS [patient information sheet] and consent forms.’
(PS12, trial manager, focus group 2)
There was general agreement that PPI should begin
earlier in the trial process in order to maximise the po-
tential for positive impact:
‘Somebody was doing a [research study] on a [device]
to encourage [medical condition] patients to visualise
the injured hand. It was set around a task in the
kitchen of making a cup of tea. This entire
programme was designed, and somebody spent ages
making it all pretty, to encourage a [medical
condition] patient to be able to move both hands to
make a cup of tea. One of the patients just turned
round and said, "Everyone can make a cup of tea one
handed, try doing something like buttering toast," and
the designer was just [clicks fingers] deflated like that.
I thought, 'You should have asked patients a year ago.'
So yes, that made a massive difference to the future
research because they essentially told him, 'Go back
and start again.' It proved that you really need to put
patients in much earlier, so it was very valuable.’
(PS31, trial manager, focus group 4)
‘Ideally, involve, involving the patients and people
who have experienced the condition very early on
at the research question stage. Because I’ve seen so
many times where PPI has been brought in at the
late stage, when it’s all been decided and it’s very
hard to comment on something at that stage.
There’s too much at stake. Too much would have
to change and so really right from deciding the
research question.’ (PP50, PPI contributor,
interview—in response to being asked what PPI
means to them)
PPI in choosing the research topic or question was
reported by fewer than one quarter of trials, while
PPI in developing the funding application and data
collection tools were each reported by approximately
half of trials (Table 5). PPI plans seemed to be fluid,
with some free-text comments indicating that PPI
might be added at later stages of the trial, particularly
at dissemination.
Trials funded by the NIHR were not more likely to have
PPI in the funding application (48% vs. 41%; 7% difference,
95% CI −19 to 31%), nor were trials with a recruitment
start date on or after the median of 1st July 2013 (54% vs.
38%; 16% difference, 95% CI −7 to 37%).
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PPI roles within surgical trials
The majority of surveyed trials had at least one PPI con-
tributor on the Trial Steering Committee (72%), while
fewer had a PPI contributor as grant co-applicant (35%)
and/or member of the Trial Management Group (35%)
(Table 6). Over 60% of trials also consulted PPI contrib-
utors out-with these roles; methods included focus
group or group discussion (n = 25), interviews (n = 21),
email consultation (n = 11), survey (n = 6), online group
discussion or forum (n = 1), and other informal methods.
Other roles mentioned by survey respondents in
free-text included PPI membership of the independent
Data Monitoring Committee (n = 1) and PPI in investi-
gator training and interviewing for the trial physician
post (n = 1).
Despite PPI co-applicants being present in over
one-third of surveyed trials, there was evidence that this
was sometimes tokenistic, as illustrated by survey respond-
ent SR50, a trial manager: ‘…they [PPI co-applicants] were
listed on the grant but I do not think they had much input
to the design.’
An interesting finding was the use of a two-tier model
of PPI by several trials, in which a smaller number of
PPI contributors were closely and regularly involved
with the trial team, linked to a larger group of patients
who were consulted intermittently. This model was seen
as beneficial because it resulted in better patient engage-
ment due to greater relevance and the opportunity for
social networking:
‘I've been using patient panels rather than individual
patients, because my experience of using individual
Table 5 Patient and public involvement (PPI) in stages of the
research process (n = 71)
Number of trials (%)
Research design 58 (81.7%)
• Research topic or question 16 (22.5%)
• Funding application 33 (46.5%)
• Intervention design 21 (29.6%)
• Participant information materials
(e.g. information sheets, consent forms,
recruitment adverts)
51 (71.8%)
• Data collection tools (e.g. questionnaires,
interview schedules)
36 (50.7%)
• Recruitment methods 29 (40.8%)
• Retention methods 19 (26.8%)
• Do not know 1 (1.4%)
• Othera 2 (2.8%)
Undertaking the research 17 (23.9%)
• Promoting the trial to encourage recruitment 9 (12.7%)
• Identifying or screening potential participants 8 (11.3%)
• Taking consent from participants 1 (1.4%%)
• Collecting research data 2 (2.8%%)
• Do not know 2 (2.8%)
• Otherb 1 (1.4%)
Analysis and/or interpretation of results 22 (31.0%)
• Analysing research data 3 (4.2%)
• Interpreting data or results 16 (22.5%)
• Do not know 1 (1.4%)
• Otherc 3 (4.2%)
Dissemination of findings 42 (59.2%)
• Writing or reviewing research reports 11 (15.5%)
• Writing or reviewing lay summaries 32 (45.1%)
• Presenting the findings at a research conference 6 (8.5%)
• Presenting the findings to a lay audience 24 (33.8%)
• Suggesting routes/platforms for dissemination 30 (42.3%)
• Do not know 3 (4.2%)
• Other 0 (0.0%)
None of the above 0 (0.0%)
Otherd 2 (2.8%)
aOutcome measures (n = 2)
bDeveloping a video/DVD to aid informed consent (n = 1)
cReviewing interim reports at Trial Steering Committee (TSC) meetings (n = 1);
discussing results with PPI group (n = 2)
dGeneral oversight or management of the research (n = 2)
Table 6 Patient and public involvement (PPI) contributor roles
within surgical trials (n = 71)
Number of trials (%)
Co-applicant(s) on grant 25 (35.2%)
• 1 co-applicant 23 (32.4%)
• 2 co-applicants 2 (2.8%)
Formal member(s) of Trial Management
Group or equivalent study team
25 (35.2%)
• 1 member 15 (21.1%)
• 2 members 8 (11.3%)
• 3 members 2 (2.8%)
Member(s) of Trial Steering Committee 51 (71.8%)a
• 1 member 31 (43.7%)
• 2 members 16 (22.5%)
• 3 or more members 2 (2.8%)
Consultee(s) 45 (63.4%)b
• 1–5 consultees 11 (15.5%)
• 6–10 consultees 10 (14.1%)
• 11–20 consultees 9 (12.7%)
• More than 20 consultees 5 (7.0%)
aTwo trials did not have a Trial Steering Committee at the time of
survey completion
bIncludes focus group or group discussion (n = 25), interviews (n = 21), email
consultation (n = 11), survey (n = 6), online group discussion or forum (n = 1),
and other informal methods (n = 7). In the case of 10 trials, all or part of this
consultation was a formal research project (requiring ethics approval and
informed consent from participants)
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patients within surgical trials has not been good
because of non-attendance and non-engagement. So,
I've had much more success in creating panels of
patients who have one or two representatives of those
panels who'll come to steering groups to represent the
group as a whole.’ (PS19, principal investigator, focus
group 3)
‘If you do it in a bigger forum where at least there's
more than one PPI person, if you do it in a group,
then I think they’ll feel like they can engage better and
they’ve got somebody else there with them that they
can connect with, and they don’t feel like they're there
by themselves. […] I think that’s the best way of really
getting patients talking to each other, exchanging
ideas and really feeling like they're involved in the
study.’ (PS12, trial manager, focus group 2)
‘We found it's worked really well to have it separate
actually, and you can just focus on the things that
need talking about with them, rather than I suppose
them having to sit through an entire meeting where
maybe only certain bits of it might be relevant for
them. […] I think it started off working well and then
it didn’t and they couldn’t attend the meetings and it
just wasn’t working, so we took a different approach
and so far it seems to be working well. […] In
addition to how it helps the trial, I think patients
really value coming along to a meeting of just patients
and just all sharing their stories actually.’ (PS24, PPI
coordinator, focus group 4)
However, one participant warned of the difficulty
initiating this kind of arrangement, because ‘the Trial
Manager is often not involved in the trial when this sort
of group needs to be set up’ (SR69, trial manager, survey
respondent).
Use of PPI role descriptions
When asked the question ‘Has/have the PPI contribu-
tor(s) been given a written document outlining their
role(s) in this specific trial?’, only 10 (15.4%) surveyed
trials with PPI responded ‘yes—all PPI contributors’ and
17 (26.2%) responded ‘yes—some PPI contributors’. Des-
pite these low frequencies, role descriptions were viewed
by both surgical trial staff and PPI contributors as useful
tools for recruiting suitable and diverse PPI contributors,
and even necessary from an ethics point of view:
‘There’s something about actually understanding what
it is that you’re wanting from your PPI, and actually
having a role description and making sure that what
you’re doing is matching people against those role
descriptions. So, that might be about how much time
is going to be involved in it. It might be about the
cultural aspects of it. It might be about we need
somebody who’s going to be able to go out there and
sell it, whatever it is, but you need to be able to
encapsulate that but you also need to be able to make
some matching against it and not—what happens I
think quite a lot in research is that there’s just like
anybody who actually shows any sign of interest, it’s
like ‘Well, we’ll take them now!’ [laughs], and that
lowers the quality of PPI, so consequently it lowers
the inequality of the research generally.’ (PP02,
principal investigator, focus group 1)
‘But one of the other things in [Borough] as well
that was pointed out to me, was that they felt,
with hindsight, that you needed to make sure that
the PPI representatives had a very accurate
description of what their roles and responsibilities
were at the outset, so that they knew before they
actually consented to take part really, about what
they were taking on… (PS09, research nurse, focus
group 2).
Payment for PPI contributors’ time and expenses
With regard to funding for PPI, 35 (53.8%) trials had spe-
cific funding for their PPI, which was usually included in
the research grant (33 trials; 50.8%). Almost all surveyed tri-
als with PPI reimbursed PPI contributors for any travel
and/or out of pocket expenses related to their involvement:
48 (73.8%) always and 10 (15.4%) sometimes (free-text re-
sponses indicated that PPI contributors sometimes declined
or failed to claim expenses). However, PPI contributors
were usually not paid for their time related to involvement
(e.g. with vouchers, honoraria, or direct payment), with 38
(58.5%) trials reporting that this never happened. Surgical
trial staff and PPI contributors had mixed views about pay-
ment; some saw it as essential recognition of work done
and part of equalising the relationship with researchers, as
illustrated by the below conversation among PPI
contributors in focus group 5, and others as ‘interfering
with the taxman’ (PP01, PPI contributor) or potentially
attracting people for the wrong reasons:
PP03: ‘…I don’t classify it as a payment or a fee. What
I see it as [is] recognition of time sacrifices. So, if I’m
emailing yourself with anybody else I might say, ‘In
addition to my travelling expenses, would there be
any recognition of [inaudible] like two or three hours
travelling to a venue, two or three hours going back?’
And the things I have to do for my sister whilst I’m
away, who’s going to do that? Do I have to pay
somebody else? Those tasks don’t get done by
themselves, so it’s just…it’s not so much a payment as
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in, going to work and getting paid a hundred and fifty
or two hundred pounds a day, it’s a recognition of the
times I’ve…it’s a small amount, that’s all we ask for
but, a recognition.’
PP04: ‘And you’re seriously considered as a partner
then or something…a serious partner.’
PP02: ‘It’s something about the recognition within the
group that you’re dealing with…you’ve got everybody
else who sits round the table with you—health
economists, statisticians, clinicians or what have you,
who are being paid, and therefore I think that the way
that they treat you is almost as an amateur because
you’re seen as an amateur, and the more that we can do
to professionalise it almost for that…’ (focus group 5)
‘… I think PPI is taking off in a big way, I’m not sure if
it’s for the right reasons because now there’s always a
payment with it, isn’t there? But on saying that if
someone’s got a job and they have to take time off work
they need to be paid. If they’ve got carers, they need to
be paid.’ (PP04, PPI contributor, focus group 5)
‘We had one [PPI rep] who was what we consider a
“professional patient” and they charged for their
time—quite a lot of money. The other PPI rep did not
do this and I feel we got more from the unpaid rep as
they were doing it out of the goodness of wanting to
help rather than trying to make money from it and
contributing in a tokenistic manner.’ (SR54, trial
manager, survey)
Discussion
Main findings
Our survey findings suggest that PPI has started to be-
come routine practice for UK surgical trials, with over
90% of surveyed trials reporting some kind of PPI. Patients
and members of the public were reportedly involved in a
variety of different ways, most commonly at the design
and dissemination stages (relative to the trial conduct and
data analysis stages) and in oversight or advisory roles
(relative to partnership or management roles). The single
most common PPI activity was developing participant in-
formation sheets (72% of surveyed trials), but there was
evidence that this was sometimes tokenistic, and general
agreement that PPI should be started earlier in surgical
trial design. A two-tier model of PPI, in which a small
number of PPI contributors are closely involved with the
trial team and linked to a larger group of patients, was
seen as beneficial because it resulted in a better represen-
tation and patient engagement than the involvement of
one or two PPI contributors alone. This is consistent with
the finding of a realist evaluation that a similar ‘outreach’
model of PPI, in which lay representatives are linked to
broader communities, was an effective and efficient model
of PPI in clinical research [26].
Almost none of the surveyed trials included partici-
pants from the trial as PPI contributors. However, one
PPI focus group participant suggested that input from
trial participants would be a useful form of PPI, and
expressed frustration that participants are difficult to ac-
cess for this purpose. Vale et al. recently recommended
that PPI guidance be updated to routinely consider in-
cluding participants as part of wider PPI plans [27].
PPI contributors usually had personal experience of
the condition under study (either as patients or carers),
and this experiential knowledge was viewed by some as
being a crucial attribute of PPI. Nevertheless, public
contributors without such experience could bring advan-
tages for the trial team too, such as impartiality and a
greater ability to commit to the long-term trial in some
medical contexts. This is consistent with previous re-
search which identified the ‘expert in lived experience’ as
only one of several potential roles embodied by PPI con-
tributors [12].
PPI contributors were recruited most commonly via a
clinician on the team; other means had proved difficult
for some participants, and a database or pool of inter-
ested people was suggested as a potentially useful re-
source for surgical trialists. Formal role descriptions for
PPI contributors were not commonly used, but were
viewed as a potentially useful tool for recruitment of
suitable candidates. Reimbursement of PPI contributors’
expenses was common practice, but payment for time
was less common, and participants had mixed feelings
about the appropriateness of payment.
Many of the challenges and views identified in this
study are not unique to surgical trials and have been
widely reported for PPI in clinical trials and health re-
search more broadly, including tokenism, lack of clarity
around PPI roles, difficulty recruiting and retaining PPI
contributors, and issues around payment and funding
[11, 16, 28–31]. We did not identify any unique,
stand-alone issues that would apply to surgical trials but
not to other types of trials, although the relative import-
ance of some of the shared issues and uncertainties may
differ (a question beyond the scope of this study).
It is worth noting that some of the discourses identi-
fied in this study have been or could be critiqued. For
example, the common view that some PPI contributors
are too ‘professionalised’ for the role has been criticised
as oversimplistic34. Some training and/or expertise is
often helpful, and the degree and type required (or not)
will vary according to the specific role. The cronyism of
clinical investigators choosing favourite patients as PPI
contributors was criticised but is consistent with the
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manner in which many other research team members
(e.g. the statistician or health economist) are routinely
chosen. It perhaps reflects the view that part of a PPI
contributor’s role is to be a ‘challenging outsider’11 , and
that this may not be possible if investigators have a
tokenistic attitude towards PPI (deliberately choosing
people they anticipate will be compliant) or if there is an
inherent power imbalance, such as when clinical investi-
gators choose their own current patients. Whilst involv-
ing current patients may be unwise, we would argue that
choosing former patients with whom clinical investiga-
tors already have a positive relationship is not necessarily
a bad thing, and in fact may be beneficial, since success-
ful PPI appears to depend on establishing and maintain-
ing good interpersonal relationships [26, 32].
Strengths and limitations
Our survey yielded a high response rate relative to sur-
veys of PPI practice in health research more broadly [16]
and was not subject to significant response bias. How-
ever, our findings may be somewhat historical, since PPI
practice is changing rapidly [19] and many of the trials
in our sample began several years ago. PPI is likely to be
even more common and more embedded now than it
was when we conducted our survey.
Another limitation is that this was not a true
mixed-methods study, but rather a quantitative study
followed by a qualitative study. While there was some
overlap between the survey respondents and focus group
participants, we deliberately sought a wider range of per-
spectives for the focus groups (including, for example,
PPI contributors and research nurses); therefore, some
of the surgical trials mentioned by focus group partici-
pants may not have been included in the survey and vice
versa. Nevertheless, we believe that the qualitative
dataset helps shed some light on the ‘real-life’ experi-
ences and views surrounding the PPI practices identified
in the survey.
None of the focus group or interview participants
questioned whether PPI should be performed in surgical
trials, nor were we able to recruit any of the few survey
respondents with negative beliefs about PPI, suggesting
that the findings may not include the full range of views
on this topic. Finally, we struggled to recruit eligible
industry-sponsored trials to this study, succeeding with
only one of eight identified. Our findings are therefore
based almost exclusively on trials sponsored by academic
institutions and the National Health Service and may
not be generalisable to commercial trials.
Implications for surgical trials and future research
The findings of this study will inform the development
of a robust PPI intervention aimed at improving recruit-
ment and retention in surgical trials (PIRRIST), which
enhances rather than duplicates baseline PPI practice.
The findings may also help surgical trialists planning PPI
for new trials; the survey findings provide a benchmark
against which they could assess their plans (how do their
PPI plans compare with their peers?), while the focus
group findings highlight some of the advantages and dis-
advantages of different PPI practices. Further research
exploring how best to involve the public and patients in
the design stage of surgical trials, including the benefits
and challenges of involving trial participants as PPI con-
tributors, would be valuable.
Conclusions
PPI has started to become routine practice in academic-
and NHS-sponsored UK-based surgical trials, most com-
monly involving one or two patients in advisory or over-
sight roles such as membership of the Trial Steering
Committee. However, there is potential for, and signs of
a shift towards, much greater and earlier involvement.
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